After two decades in Clinical Ops, here’s the pattern I’ve seen:

The moment you award a vendor, the dynamics shift.

Before the contract is signed, you have choices. After it’s signed, you have commitments.

That shift has real consequences, especially when something in your trial inevitably changes — because something always changes.

What Actually Happens When You Lock In a Vendor

Once a CRO or vendor is locked in, negotiating becomes harder. Not because anyone is acting in bad faith, but because:

  • You can’t replace them without significant fallout.

  • Every deviation becomes a potential “out of scope.”

  • Your options narrow, sometimes dramatically.

Mid-study vendor changes are technically possible but practically painful. Most sponsors won’t do it unless things are truly falling apart. Vendors know this :-).

That’s why the early phase — before the award — is where your real influence lives.

A Story I’ll Never Forget: When a 140% Change Order Crippled a Small Biotech

I once supported a small biotech. Strong science, good people, and a CRO that looked good ... on paper at least.

Then the study strategy had to shift. A major amendment. A major operational pivot. A change order that was 140% of the original budget.

The CRO couldn’t keep up — not because they were incapable technically, but because they weren’t built for the level of flexibility the situation demanded. The sponsor wanted to keep the study moving while controlling costs. The CRO wanted protection from the growing complexity and workload.

What should have been a strategic adjustment turned into:

  • Endless debate

  • Delays

  • Strained relationships

  • And eventually, concerns around data quality

The real lesson wasn’t “change orders are expensive.” The lesson was: we had picked the wrong partner months before the amendment ever happened.

You don’t feel the impact of a poor vendor choice immediately. It catches up to you when the trial hits turbulence.

Why Vendor Fit Matters More Than the Budget Line

Most sponsors compare CROs on cost, timelines, or capability slides. Those matter, of course. But what matters even more is something harder to quantify:

Can this vendor actually partner with you when the study stops being straightforward?

That’s the difference I’ve seen over and over again between trials that move forward and trials that get stuck.

You want a team that:

  • Communicates like adults

  • Doesn’t nickel-and-dime every twist and turn

  • Flags risks early

  • Adjusts without theatrics

  • Acts like they’re on the same side of the table

You don’t get that from capability slides. You see it in how they engage during the RFQ/RFI stage — the one moment when you still hold the cards.

Your Best Leverage Point Is Before Anything Starts

The RFI/RFP process is where you can actually compare vendors side by side, ask the hard questions, and understand what you’re really buying.

The problem is: most sponsors rush through this part. They’re eager to start the study. They assume all CROs will “figure it out.” And then they spend the next three years trying to fix what should’ve been identified upfront.

That’s one of the big reasons we ended up building ClinAI. Not to “sell software,” but to fix a problem that clinical teams, including myself, ran into for decades.

The goal was simple: give sponsors a clear picture earlier, so they don’t lose leverage later.

What the platform really does is bring everything into one place so teams can actually see:

  • How each vendor is thinking

  • Where their assumptions differ

  • What their budgets really include

  • Whether the timelines make sense

  • And most importantly, whether they’re the right long-term partner

When you finally have clean, side-by-side insights instead of scattered spreadsheets, conversations with vendors become more honest, decisions become more confident, and you hold onto your leverage longer — because you're choosing with full visibility, not guesswork.

Use Your Leverage at the Only Time You Truly Have It

If I’ve learned one lesson that applies to every trial, it’s this:

You can’t fix a poor vendor choice with later negotiations. You can only try to survive it.

Your influence is highest right at the beginning — before the award. That’s the moment you should treat with the most discipline.

Choose the partner who won’t disappear when the study gets messy. Because it will. And you need someone who can stand in that with you, not just someone who won a bid.

About the Author Kalyan Obalampalli (KO) is the Founder and President of Clin.AI, a disruptive start-up transforming how biotech and pharma sponsors select and manage vendors. With more than 20 years of leadership experience in clinical operations and outsourcing at major pharma and biotech companies, KO brings a unique perspective on how technology can close long-standing gaps in clinical development.💪🌐 #ClinicalTrials #VendorSelection #CROs #Biotech #ClinOps #LeverageBeforeYouLoseIt

About Clin.AI: At Clin.AI, we help sponsors select and manage their vendors more effectively — making it easier to keep studies on track, within budget, and delivered on time. If you’d like to strengthen your vendor oversight and gain real-time visibility into the progress of your trials, give us a call. We’d be happy to walk you through how we can support your goals.

If that resonates with you, we’d love to show you how Clin.AI works. 👉 Schedule a Demo

#ClinicalTrials #VendorSelection #CROs #Biotech #ClinOps #LeverageBeforeYouLoseIt